33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma
    Meeting Abstract

    Piperno-Neumann, S.; Kapiteijn, E.; Larkin, J. M. G.; Carvajal, R. D.; Luke, J. J.; Seifert, H.; Roozen, I.; Zoubir, M.; Yang, L.; Choudhury, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Landscape of genetic alterations in patients with metastatic uveal melanoma
    Meeting Abstract

    Piperno-Neumann, S.; Kapiteijn, E.; Larkin, J. M. G.; Carvajal, R. D.; Luke, J. J.; Seifert, H.; Roozen, I.; Zoubir, M.; Ramkumar, T.; Emery, C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in subjects with advanced non-small cell lung cancer
    Meeting Abstract

    Pinder, M. C.; Rizvi, N. A.; Goldberg, S. B.; Balmanoukian, A. S.; Narwal, R.; Robbins, P. B.; D'Angelo, G.; Blake-Haskins, A.; Karakunnel, J. J.; Antonia, S. J.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • HER2 mutations in lung adenocarcinoma: A report from the Lung Cancer Mutation Consortium (LCMC)
    Meeting Abstract

    Pillai, R. N.; Behera, M.; Berry, L. D.; Rossi, M. R.; Kris, M. G.; Bunn, P. A.; Khuri, F. R.; Ramalingam, S. S.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC)
    Meeting Abstract

    Pietanza, M. C.; Krug, L. M.; Varghese, A. M.; Fleisher, M.; Teitcher, J. B.; Holodny, A.; Sima, C. S.; Litvak, A. M.; Ng, K. K.; Patel, P. R.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Feasibility and results of a randomized phase Ib study of fractionated 90{Upsilon}-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies
    Meeting Abstract

    Picozzi, V. J.; Ramanathan, R. K.; Lowery, M. A.; Ocean, A. J.; Mitchell, E. P.; O'Neil, B. H.; Guarino, M. J.; Conkling, P. R.; Cohen, S. J.; Bahary, N.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L), or their combination (T plus L) in the adjuvant treatment of HER2-positive early breast cancer (EBC)
    Meeting Abstract

    Piccart-Gebhart, M. J.; Holmes, A. P.; Baselga, J.; de Azambuja, E.; Dueck, A. C.; Viale, G.; Zujewski, J. A.; Goldhirsch, A.; Santillana, S.; Pritchard, K. I.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL)
    Meeting Abstract

    Phillips, A. A.; Fields, P.; Hermine, O.; Taylor, G.; DelloukIna, M. L.; Horwitz, S. M.; Ramos, J. C.; Menlane, J. C.; Barta, S. K.; Or, K. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC
    Meeting Abstract

    Pennell, N. A.; Neal, J. W.; Chaft, J. E.; Azzoli, C. G.; Jänne, P. A.; Govindan, R.; Evans, T. L.; Costa, D. B.; Rosovsky, R. P. G.; Wakelee, H. A.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE)
    Meeting Abstract

    Patel, J. N.; Jiang, C.; Hertz, D. L.; Mulkey, F.; Friedman, P. N.; Halabi, S.; Ratain, M. J.; Morris, M. J.; Small, E. J.; Owzar, K.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save